Sanders Morris Harris’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Sanders Morris Harris’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,000	Closed	-$4K	–	295
2022 Q3	$4K	Hold	15,000	–	–	﹤0.01%	293
2022 Q2	$5K	Hold	15,000	–	–	﹤0.01%	288
2022 Q1	$10K	Hold	15,000	–	–	﹤0.01%	301
2021 Q4	$35K	Sell	15,000 -20,000	-57%	-$67.7K	0.01%	306
2021 Q3	$160K	Buy	35,000 +20,000	+133%	+$88K	0.03%	290
2021 Q2	$67K	Buy	+15,000	New	+$76.3K	0.01%	315

Sanders Morris Harris's LOGC Position: Q4 2022 in Review

Sanders Morris Harris sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 15,000 shares — an estimated $4K sold.

Sanders Morris Harris first reported a position in LOGC in Q2 2021 and held it in 6 quarters. The position peaked at $160K in Q3 2021. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

Sanders Morris Harris reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Sanders Morris Harris sold 15,000 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $4K.
Sanders Morris Harris first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2021 and held it in 6 quarters.
Sanders Morris Harris's LogicBio Therapeutics, Inc. Common Stock position peaked at $160K in Q3 2021.
0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Sanders Morris Harris's 13F filing for Q4 2022, filed 13 Jan 2023.